Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Phase IIa results for WBI-1001 atopic dermatitis cream

Positive results from a phase IIa clinical trial testing two concentrations (0.5% and 1.0%) of WBI-1001, a new, nonsteroidal, topical cream treatment for atopic dermatitis (AD), showed that both cream concentrations were superior to placebo in deceasing AD, with an excellent safety profile. The clinical phase IIa trial for WBI-1001 was a randomized, double-blind, placebo-controlled study conducted in Montreal with the objectives of evaluating the safety and efficacy of the cream on topically treated patients. A total of 36 patients with mild to moderate AD were treated with 0.5% or 1% of WBI-1001 cream or placebo twice daily for 28 days. No serious side effects were reported in any of the ...